Results 1 to 10 of about 11,105 (147)

Investigation of the functional hot-spot residues of an enzyme by real-time monitoring of the enzymatic reaction using NMR and computational approaches [PDF]

Scientific Reports
Favipiravir is an anti-influenza prodrug that is metabolized to its phosphoribosylated form, favipiravir-ribofuranosyl-5′-monophosphate (favipiravir-RMP), by human endogenous enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT).
Toshihiko Sugiki, Tomoki Yoshida, Masaki Tsukamoto, Koichiro Miyanishi, Akinori Kagawa, Natsuko Miura, Tomoto Ura, Jun Fukazawa, Yuko Hatanaka, Tsuyoshi Murata, Toshimichi Fujiwara, Masahiro Kitagawa, Yasushi Morita, Kumiko Sakai-Kato, Yoichi Takakusagi, Nobutada Tanaka, Makoto Negoro   +16 more
doaj   +2 more sources

Dysregulated glycerophospholipid metabolism in amygdala may mediate favipiravir-induced anxiety-like behaviors in mice [PDF]

Frontiers in Pharmacology
Favipiravir, the first RNA polymerase inhibitor approved to treat resistant influenza, has been reported to be associated with central nervous system (CNS) side effects, particularly anxiety-like behavior; nevertheless, the underlying mechanism remains ...
Yuzhou Xiao, Chunqi Liu, Xiaojie Wang, Hongchun Li, Liang Wang, Kun Gou, Xingchen Liu, Xinqi Guan, Xia Zhou, Xiumei He, Yue Zhao, Lei Tao, Xiaodan Pan, Linhong Jiang, Yaxing Chen, Huan Liu, Yanping Dai, Qian Bu, Meng Qin, Ruiming Zhu, Bo Chen, Angelo D. Flores, Yinglan Zhao, Xiaobo Cen   +23 more
doaj   +2 more sources

Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients

International Journal of Infectious Diseases, 2022
Objectives: Favipiravir is an antiviral that is being evaluated for the treatment of COVID-19. Use of favipiravir is associated with elevation of serum uric acid levels. Risk factors for the occurrence of hyperuricemia are unclear.
Takenao Koseki, Kazuki Nakajima, Hitoshi Iwasaki, Shigeki Yamada, Kazuo Takahashi, Yohei Doi, Tomohiro Mizuno   +6 more
doaj   +1 more source

Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study

Journal of Infection and Public Health, 2021
Objective: To assess the efficacy of Favipiravir compared to the standard therapy in treating patients with severe COVID-19 infection. Methods: This is a retrospective cohort of patients with COVID-19 pneumonia who were treated with favipiravir, versus ...
Zainab Almoosa, Mustafa Saad, Samer Qara, Mahmoud Mustafa, Ali Mansour, Duaa Alshab, Jehad Alhashem, Sajida ALKhawajah, Saleh Alkhalifah, Mokhtar ALmarzooq, Mohammed ALzain, Neda’a Anshasi, Gasmelseed Ahmed, Abbas Al Mutair   +13 more
doaj   +1 more source

Fluorescence of ocular surface in a Covid -19 patient after Favipiravir treatment: a case report

Virology Journal, 2021
Background Favipiravir is used in treatment of Covid-19 patients. We aimed to share of ocular surface fluorescence in a patient after Favipiravir treatment in this case report.
Mehmet Ali Doran, Hasan Aytogan, Emre Ayıntap   +2 more
doaj   +1 more source

Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study

Journal of Infection and Public Health, 2022
We retrospectively investigated the clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥ 24 h of favipiravir were assigned to the favipiravir group, while those who did not ...
Rand A. Alattar, Shiema Abdalla, Tasneem Abdallah, Rashid Kazman, Aseelah Qadmour, Tawheeda Ibrahim, Bassem Alhariri, Shahd H. Shaar, Abeer Bajwa, Abeir Alimam, Rabia Qazi, Fatma Ben Abid, Joanne Daghfal, Ali Eldeeb, Kinda Shukri, Ahmed Elsayed, Fatima Rustom, Musaed Alsamawi, Alaaeldin Abdelmajid, Miguel A.P. Basulto, Armando A.R. Cobian, Mohamed Abukhattab, Abdullatif Alkhal, Muna A. Almaslamani, Ali S. Omrani   +24 more
doaj   +1 more source

Pharmacokinetic Interaction Between Favipiravir and Amlodipine in Hypertensive Local Rabbits (Oryctolagus cuniculus)

The Iraqi Journal of Veterinary Medicine, 2023
In the treatment of COVID-19, the antiviral medication Favipiravir has proven to be quite successful. Its metabolism is mediated by the enzymes aldehyde oxidase (AO) and xanthine oxidase (XO).
Ali I Al-ameedi, Falah M AL-Rekabi
doaj   +1 more source

A favipiravir-induced angioedema and urticaria in a COVID-19 patient

Antiviral Therapy, 2022
Although favipiravir is a promising drug for coronavirus disease 2019, some adverse effects, including skin lesions, have been reported. A 56-year-old female who was prescribed favipiravir by a filiation team following a positive severe acute respiratory
Figen Ergur Ozturk, Ayperi Ozturk, Hale Ates   +2 more
doaj   +1 more source

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir

Journal of Infection and Public Health, 2021
Background: In this study, we aimed to compare the intensive care unit (ICU) admission rate of hospitalized mild/moderate COVID-19 patients treated with hydroxychloroquine (HCQ), favipiravir, and HCQ plus favipiravir. Methods: Single center retrospective
Rahmet Guner, Imran Hasanoglu, Bircan Kayaaslan, Adalet Aypak, Esragul Akinci, Hurrem Bodur, Fatma Eser, Ayse Kaya Kalem, Orhan Kucuksahin, Ihsan Ates, Aliye Bastug, Yasemin Tezer Tekce, Zeynep Bilgic, Fahriye Melis Gursoy, Hatice Nisa Akca, Seval Izdes, Deniz Erdem, Emra Asfuroglu, Habibe Hezer, Hatice Kilic, Musa Cıvak, Sibel Aydogan, Turan Buzgan   +22 more
doaj   +1 more source

The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers

Brazilian Journal of Infectious Diseases, 2022
Objectives: Comparative data on hydroxychloroquine and favipiravir, commonly used agents in the treatment of Coronavirus Disease-2019 (COVID-19), are still limited.
Derya Bayırlı Turan, Mehtap Menteş, Yıldıran Özel, Kıvanç Şerefhanoğlu, Burcu Aydoğan, Neşe İbil, Füsun Güneşdoğdu, Hijran Mammadova Orucova, Cüneyt Saltürk, Hakan Çelik   +9 more
doaj   +1 more source